Telmisartan/hydrochlorothiazide: In the treatment of essential hypertension

Drugs

Volumn 63, Issue 19, 2003, Pages 2013-2026

  Fenton, Caroline ^a   Keating, Gillian M ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; ENALAPRIL; HYDROCHLOROTHIAZIDE; IRBESARTAN; LISINOPRIL; LOSARTAN; TELMISARTAN;

ANGINA PECTORIS; ANGIONEUROTIC EDEMA; AREA UNDER THE CURVE; BLOOD PRESSURE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; COUGHING; DIABETES MELLITUS; DIARRHEA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TOLERABILITY; ESSENTIAL HYPERTENSION; FATIGUE; HEADACHE; HEART ATRIUM FIBRILLATION; HEART PALPITATION; HEMATEMESIS; HUMAN; HYPERURICEMIA; HYPOKALEMIA; HYPOTENSION; KIDNEY DISEASE; LIVER FAILURE; NONHUMAN; PATIENT COMPLIANCE; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; TACHYCARDIA; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VERTIGO;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BENZIMIDAZOLES; BENZOATES; CLINICAL TRIALS; DIURETICS; DRUG COMBINATIONS; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION;

ANGINA;

EID: 0141637470     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200363190-00006     Document Type: Review

References (42)

1. McGill JB, Reilly PA. Telmisartan plus hydrochlorothiazide versus telmisartan or hydrochlorothiazide monotherapy in patients with mild to moderate hypertension: a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial. Clin Ther 2001 Jun; 23 (6): 833-50
2. Freytag F, Holwerda NJ, Karlberg BE, et al. Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11 (3): 173-81
3. Lacourcière Y, Martin K. Comparison of a fixed-dose combination of 40 mg telmisartan plus 12.5 mg hydrochlorothiazide with 40 mg telmisartan in the control of mild to moderate hypertension. Am J Ther 2002 Mar-Apr; 9 (2): 111-7
4. Lacourcière Y. A new fixed-dose combination for added blood pressure control: telmisartan plus hydrochlorothiazide. J Int Med Res 2002 Jul-Aug; 30 (4): 366-79
5. Lacourcière Y, Tytus R, O'Keefe D, et al. Efficacy and tolerability of a fixed-dose combination of telmisartan plus hydrochlorothiazide in patients uncontrolled with telmisartan monotherapy. J Hum Hypertens 2001 Nov; 15 (11): 763-70
6. Sharpe M, Jarvis B, Goa KL. Telmisartan: a review of its use in hypertension. Drugs 2001; 61 (10): 1501-29
7. Maillard MP, Perregaux C, Centeno C, et al. In vitro and in vivo characterization of the activity of telmisartan: an insurmountable angiotensin II receptor antagonist. J Pharmacol Exp Ther 2002 Sep; 302 (3): 1089-95
8. 1-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery. J Cardiovasc Pharmacol 2001 Jul; 38 (1): 141-8
9. Stangier J, Su CA, van Heiningen PN, et al. Inhibitory effect of telmisartan on the blood pressure response to angiotensin II challenge. J Cardiovasc Pharmacol 2001 Nov; 38 (5): 672-85
10. Forclaz A, Maillard M, Nussberger J, et al. Angiotensin II receptor blockade: is there truly a benefit of adding an ACE inhibitor? Hypertension 2003 Jan; 41: 31-6
11. Burgess ED, Buckley S. Acute natriuretic effect of telmisartan in hypertensive patients [abstract no. 1025]. Am J Hypertens 2000 Apr; 13 (Pt 2): 183
12. Burgess ED, Buckley S. Long-term effect of telmisartan on odium excretion in hypertensive patients [abstract no. 58]. Can J Cardiol 2000 Sep; 16 Suppl. F: 106
13. Weber M. The telmisartan programme of research to show telmisartan end-organ protection (PROTECTION) programme. J Hypertens 2003; 21 Suppl. 6: S37-46
14. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in man. Eur J Clin Pharmacol 1977 Dec 2; 12 (4): 297-303
15. Ripley E, King K, Sica DA. Racial differences in response to acute dosing with hydrochlorothiazide. Am J Hypertens 2000; 13 (2): 157-64
16. van Brummelen P, Man in 't Veld AJ, Schalekamp MADH. Hemodynamic changes during long-term thiazide treatment of essential hypertension in responders and non-responders. Clin Pharmacol Ther 1980 Mar; 27 (3): 328-36
17. Pickkers P, Hughes AD, Russel FGM, et al. Thiazide-induced vasodilation in humans is mediated by potassium channel activation. Hypertension 1998 Dec; 32: 1071-6
18. Pickkers P, Garcha RS, Schachter M, et al. Inhibition of carbonic anhydrase accounts for the direct vascular effect of hydrochlorothiazide. Hypertension 1999 Apr; 33: 1043-8
19. Wienen W, Schierok HJ. Effects of telmisartan, hydrochlorothiazide and their combination on blood pressure and renal excretory parameters in spontaneously hypertensive rats. J Renin Angiotensin Aldosterone Syst 2001 Jun; 2 (2): 123-8
20. Yong CL, Dias VC, Stangier J. Multiple-dose pharmacokinetics of telmisartan and of hydrochlorothiazide following concurrent administration in healthy subjects. J Clin Pharmacol 2000 Dec; 40 (12 Pt 1): 1323-30
21. 14C]telmisartan in healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1312-22
22. Stangier J, Su CAPF, Roth W. Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000 Jul-Aug; 28: 149-67
23. 1 receptor antagonist telmisartan in patients with mild to moderate hypertension. Adv Ther 1998 Jul-Aug; 15: 206-17
24. Stangier J, Su C-APF, Schondorfer G, et al. Pharmacokinetics and safety of intravenous and oral telmisartan 20 mg and 120 mg in subjects with hepatic impairment compared with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1355-64
25. Stangier J, Heinzel G, Su C-A, et al. Clinical pharmacokinetics of telmisartan [abstract no. P.49]. J Hum Hypertens 1999 May; 13 Suppl. 3: 13
26. Patel RB, Patel UR, Rogge MC, et al. Bioavailability of hydrochlorothiazide from tablets and suspensions. J Pharm Sci 1984 Mar; 73 (3): 359-61
27. Barbhaiya RH, Craig WA, Corrick-West HP, et al. Pharmacokinetics of hydrochlorothiazide in fasted and nonfasted subjects: a comparison of plasma level and urinary excretion methods. J Pharm Sci 1982 Feb; 71 (2): 245-8
28. Chen TM, Chiou WL. Large differences in the biological halflife and volume of distribution of hydrochlorothiazide in normal subjects from eleven studies. Correlation with their last blood sampling times. Int J Clin Pharmacol Ther Toxicol 1992 Jan; 30 (1): 34-7
29. Niemeyer C, Hasenfuss G, Wais U, et al. Pharmacokinetics of hydrochlorothiazide in relation to renal function. Eur J Clin Pharmacol 1983; 24 (5): 661-5
30. Boehringer Ingelheim. Telmisartan prescribing information. 2000
31. Stangier J, Su C-APF, Brickl R, et al. Pharmacokinetics of single-dose telmisartan 120 mg given during and between hemodialysis in subjects with severe renal insufficiency: comparison with healthy volunteers. J Clin Pharmacol 2000 Dec; 40 Pt 1: 1365-72
32. Hannedouche T, Chanard J, Baumelou B. Evaluation of the safety and efficacy of telmisartan and enalapril, with the potential addition of frusemide, in moderate-renal failure patients with mild-to-moderate hypertension. J Renin Angiotensin Aldosterone Syst 2001 Dec; 2 (4): 246-54
33. Beermann B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol 1979 Jun; 7 (6): 579-83
34. Lacourcière Y, Gil-Extremera B, Mueller O, et al. Efficacy and tolerability of fixed-dose combinations of telmisartan plus HCTZ compared with losartan plus HCTZ in patients with essential hypertension. Int J Clin Pract 2003 May; 57: 237-79
35. Neutel JM, Klein C, Meinicke TW, et al. Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11 (5): 302-9
36. Freytag F, Schelling A, Meinicke T, et al. Comparison of 26-week efficacy and tolerability of telmisartan and atenolol, in combination with hydrochlorothiazide as required, in the treatment of mild to moderate hypertension: a randomized, multicenter study. Clin Ther 2001 Jan; 23 (1): 108-23
37. Karlberg BE, Lins L-E, Hermansson K. Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17 (2): 293-302
38. McGill JB, Reilly PA. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol 2001 Jan; 24 (1): 66-72
39. Boehringer-Ingelheim. Data on file. 2003
40. Lacourcière Y, Poirier L, Extremera BG, et al. Telmisartan in combination with hydrochlorothiazide or losartan in combination with hydrochlorothiazide; ABPM assessment of blood pressure lowering. Am J Hypertens 2002 Apr; 15 (Pt 2): 113
41. Mancia G. Tolerability and safety of telmisartan as monotherapy or combined with hydrochlorothiazide compared with placebo [abstract no. R194]. J Hypertens 2002 Jun; 20 (4 Suppl.): 377
42. European Agency for the Evaluation of Medicinal Products. Summary of product characteristics for telmisartan/hydrochlo-rothiazide [online]. Available from URL: http://www.emea.eu.int [Accessed 2003 May 20]